Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness [1] [2] [3] [4] . A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple treatment modalities across diverse cancer lineages, but the mechanistic underpinning for this state has remained incompletely understood [1] [2] [3] [4] [5] [6] . Here we molecularly characterize this therapy-resistant high-mesenchymal cell state in human cancer cell lines and organoids and show that it depends on a druggable lipid-peroxidase pathway that protects against ferroptosis, a nonapoptotic form of cell death induced by the build-up of toxic lipid peroxides 7, 8 . We show that this cell state is characterized by activity of enzymes that promote the synthesis of polyunsaturated lipids. These lipids are the substrates for lipid peroxidation by lipoxygenase enzymes 8, 9 . This lipid metabolism creates a dependency on pathways converging on the phospholipid glutathione peroxidase (GPX4), a selenocysteine-containing enzyme that dissipates lipid peroxides and thereby prevents the iron-mediated reactions of peroxides that induce ferroptotic cell death 8 . Dependency on GPX4 was found to exist across diverse therapy-resistant states characterized by high expression of ZEB1, including epithelial-mesenchymal transition in epithelial-derived carcinomas, TGFβ-mediated therapyresistance in melanoma, treatment-induced neuroendocrine transdifferentiation in prostate cancer, and sarcomas, which are fixed in a mesenchymal state owing to their cells of origin. We identify vulnerability to ferroptic cell death induced by inhibition of a lipid peroxidase pathway as a feature of therapy-resistant cancer cells across diverse mesenchymal cell-state contexts.
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We hypothesized that the existence of distinct cell states in cultured cells 1, 2, 4 could be exploited to discover vulnerabilities of therapy- resistant cell states by mining cancer cell-line sensitivity data for compounds whose activities correlate with bulk cell-line expression of resistance markers. To explore this, we selected three cellular and patient-derived signatures of high mesenchymal state proposed to yield a therapy-resistant state 5, 6, 10 . We first computed a mesenchymal score for 516 epithelium-derived cancer cell lines (carcinomas) used to generate small-molecule sensitivity measurements available in the Cancer Therapeutics Response Portal (CTRP at http:// portals. broadinstitute.org/ctrp.v2.2/) (Supplementary Table 1 ). Geneexpression data were obtained from the CCLE portal (https:// portals. broadinstitute.org/ccle/home) 11 . We performed single-sample gene set enrichment analysis 12 using gene-expression signatures of mesenchymal states associated with therapy resistance 5, 6, 10 . Correlating these cell-line mesenchymal scores with an area-underthe-curve (AUC) metric of cell-line sensitivity (from 16 concentrations measured in duplicate) to each of 481 performance-diverse compounds yielded a range of compound sensitivity-mesenchymal score correlation coefficients 13 ( Fig. 1a and Supplementary Table 2 ). Tyrosine kinase inhibitors known to inhibit epithelial cancer cell targets (for example, epidermal growth factor receptor) were among the compounds most correlated with epithelial cell-state sensitivity, increasing our confidence in this approach (Fig. 1a) . Also, ML239, a compound that was initially identified for its ability to preferentially kill breast cancer cells that had been induced to undergo EMT 14 , and has recently been shown to increase levels of unsaturated lipids in cancer cells 13 , correlated with mesenchymal state sensitivity, further validating this strategy ( Fig. 1a and Supplementary Table 2 ).
In addition to the lipid-modifying compound ML239 (ref. 13 ), two distinct classes of compounds strongly correlated with selective cell death induction of epithelial cancer-derived cell lines with highmesenchymal state gene-expression scores (Fig. 1a) . The first class comprises RSL3, ML210 and ML162, compounds known to induce ferroptosis, a non-apoptotic, oxidative form of regulated cell death involving lipid hydroperoxides 7, 8 (Fig. 1b) . The second class comprises fluvastatin, lovastatin acid and simvastatin, compounds (statins) that inhibit 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) (Fig. 1b) . We refer to these seven compounds collectively as mesenchymal state-targeting compounds.
The correlation of low protein levels of E-cadherin, a canonical epithelial state marker, and high protein levels of vimentin, a marker of mesenchymal states, with cell-line sensitivity to mesenchymal statetargeting compounds across a panel of eight pancreatic and gastric cancer cell lines provided further validation of the mesenchymal statetargeting effects of these compounds ( Fig. 1c and Extended Data Figs 1, 2) . In addition to exhibiting selectivity for epithelial cancerderived cell lines with high expression of mesenchymal state genes, the ferroptosis-inducing subset of mesenchymal state-targeting compounds were the most selective compounds for cancer cell lines of mesenchymal origin (sarcomas) (Fig. 1d) . Cell lines derived from ovarian and kidney cancers also demonstrated selective targeting by ferroptosis-inducing mesenchymal state-targeting compounds (Fig. 1d) . We hypothesize that this stems from the mesenchymal mesonephric embryonal origin of the ovaries and kidneys, with retention of a mesenchymal state-vulnerability in ovarian and kidney cancers arising from these tissues 15, 16 . Using publically available genome-wide short hairpin RNA (shRNA) sensitivity data for 349 cancer cell lines (http://portals.broadinstitute. org/achilles), we found that cell-line sensitivity to knockdown of GPX4 was the top correlate of sensitivity to the ferroptosis-inducing subset of compounds ( Fig. 2a and Extended Data Fig. 3 ). This suggested that the distinguishing feature of these compounds lies in their unique ability to inhibit GPX4, a hypothesis that was particularly attractive in light of the identification of GPX4 as the relevant direct target of RSL3 (ref. 8 ). GPX4, one of 25 selenocysteine-containing proteins encoded in the human genome 17 , uses glutathione as a cofactor to reduce allylic lipid hydroperoxides to their corresponding alcohols 8 . Using a lysate-based assay that reports on the ability of cellular GPX4 to reduce exogenous phosphatidylcholine hydroperoxide, we were able to confirm for RSL3 (ref. 8) and to demonstrate for ML210 and ML162, that these mesenchymal state-targeting compounds inhibit GPX4 activity (Extended Data Fig. 4) . Statins, which are small-molecule inhibitors of HMGCR, may mediate their selective cell death induction of high-mesenchymal state cancer cells (Fig. 1a) through their effects on isopentenylation of the selenocysteine-charged transfer RNA (tRNA) as part of selenocysteinetRNA maturation 18 . By inhibiting the production of isopentenyl pyrophosphate through the mevalonate pathway, statins are known to inhibit selenoprotein biosynthesis 18 . The adjacent clustering of statins and direct GPX4 inhibitors in a hierarchical clustering of the CTRP AUC-similarity matrix 11 ( Fig. 2b) , which aims to identify compounds that have similar patterns of sensitivity across hundreds of cancer cell lines, supported a mechanism of action for statins that is closely related to, albeit distinct from, that of direct GPX4 inhibitors. Treatment of cells with fluvastatin led to decreased expression of GPX4 in a time-and concentration-dependent manner ( Fig. 2c and Supplementary Fig. 1 ) and synergized with co-treatment with the direct GPX4 inhibitor RSL3 (Fig. 2d) . Unlike the effects of direct GPX4 inhibitors, statin treatment could not be rescued by lipophilic antioxidants (Extended Data Fig. 5 ). However, statin treatment led to increased levels of cellular lipid peroxidation (Fig. 2e) , consistent with inhibition of GPX4 protein expression 8 .
The existence of not just one, but multiple high-mesenchymal cancer cell states derived from different inputs has become apparent in recent years 19 . To gain a deeper insight into the relationship between these states and GPX4 dependency, we analysed several isogenic cell-line systems that model cancer-relevant mesenchymal states. High-mesenchymal state cancer cells derived from artificially enforced expression of the EMT transcription factors SNAIL1 (also known as SNAI1) or TWIST1 (refs 20, 21) did not show consistent sensitization to GPX4 inhibition (Extended Data Fig. 6 ). By contrast, we found that the EMT regulator and lipogenic factor ZEB1 (refs 22, 23) was strongly correlated with mesenchymal state sensitivity to GPX4 inhibition (Fig. 3a) . More importantly, ZEB1 deletion abolished sensitivity to GPX4 inhibition (Fig. 3b, Extended Data Fig. 7 and Supplementary Fig. 1) , showing that ZEB1 is required for the dependency of high-mesenchymal state cells on GPX4. High-mesenchymal state populations arising in response to targeted therapy represent an additional isogenic model of therapyresistant mesenchymal cancer cell states 24 . We found that HCC4006 non-small-cell lung cancer cells that have acquired a high-mesenchymal state together with resistance to gefinitib 24 were preferentially sensitive to GPX4 inhibition compared with parental HCC4006 cells ( Fig. 3c and Extended Data Fig. 8 ). Two patient-derived pancreatic cancer cell lines were found to have GPX4 inhibitor sensitivity that correlated positively with levels of mesenchymal state protein markers and inversely with sensitivity to erlotinib (Extended Data Fig. 1 ). Neuroendocrine transdifferentiation in the setting of prostate cancer has been shown to yield therapy-resistant cells with increased expression of mesenchymal state genes 25, 26 . Across a panel of patient-derived prostate cancer organoids and benign prostate cells exhibiting a range of epithelial versus mesenchymal characteristics 25 , we found therapyinduced, high ZEB1 neuroendocrine transition to be associated selectively with GPX4 dependency (Fig. 3d and Extended Data Fig. 8 ).
In the context of BRAF-mutant melanoma, a non-mutational cell state observed in human tumours has been implicated in resistance to targeted therapy and immunotherapy [1] [2] [3] [4] . This melanoma therapyresistant state resembles that of activated fibroblasts (for example, myofibroblasts) and is characterized by increased expression of mesenchymal markers including AXL, decreased expression of the melanocyte lineage-specific transcription factor MITF and can be induced in therapy-sensitive cells by treatment with TGFβ 1 . We found that a gene-expression signature 2 of this melanoma 25 is selectively sensitive to GPX4 inhibition (three technical replicates representative of two separate experiments). e, Patient-derived melanoma lines induced into a therapy-resistant mesenchymal state with TGFβ treatment acquire resistance to BRAF inhibition and sensitivity to GPX4 inhibition. f, In vitro growth curves of GPX4 wild-type (sgEGFP) and GPX4 knockout (sgGPX4) cancer cells in the presence or absence of a lipophilic antioxidant (ferrostatin-1). g, In vivo growth of GPX4-wild-type (sgEGFP; blue curves) and GPX4-knockout (sgGPX4; red curves) melanoma xenografts in mice dosed with ferrostatin-1 and upon cessation of dosing with ferrostatin-1. letter reSeArCH therapy-resistant state correlated strongly with sensitivity to GPX4 inhibitors within the CTRP (Extended Data Fig. 8 ) and that treatment of two therapy-sensitive patient-derived melanoma lines 27 with TGFβ caused resistance to BRAF inhibition and induced GPX4 dependency (Fig. 3e) .
While attempting to demonstrate that GPX4 remains intact as a mesenchymal state dependency in vivo, we were confronted by pharmacokinetic liabilities of existing GPX4 inhibitors that preclude their use in animals 8 . To circumvent this challenge, we used a genetic approach that exploits the ability of lipophilic antioxidants (for example, vitamin E (ref. 8), ferrostatin-1 (ref. 7)) to rescue the effects of GPX4 loss. We used CRISPR-Cas9 technology to knockout GPX4 across a panel of cancer cell lines (Extended Data Fig. 7 and Supplementary Fig. 1 ) with a range of mesenchymal scores. This was achieved in the presence of ferrostatin-1, allowing the survival of GPX4-knockout cells that are dependent on GPX4. Both epithelial and mesenchymal state GPX4-knockout cancer cells proliferated at rates comparable to their wild-type (GPX4-wild-type) counterparts when in the presence of ferrostatin-1 (Fig. 3f) . Withdrawal of ferrostatin-1 uncovered the loss of GPX4 function, inducing ferroptosis in mesenchymal state GPX4-knockout cells, whereas epithelial state GPX4-knockout cells remained unaffected (Fig. 3f) .
We adapted this approach to an in vivo context by optimizing a ferrostatin-1 dosing strategy for mice that enabled the survival of GPX4-dependent GPX4-knockout cancer cells injected subcutaneously. We generated xenografts of both GPX4-wild-type and GPX4-knockout clones of the high-mesenchymal state, therapy-resistant melanoma cell line LOXIMVI (Fig. 3g) . Cessation of ferrostatin-1 dosing led to tumour regression selectively in the GPX4-knockout xenograft, whereas the GPX4-wild-type xenograft continued to grow rapidly (Fig. 3g ). These results demonstrate in a cell-autonomous context that mesenchymal state dependency on GPX4 remains intact in vivo, despite potential differences between in vitro and in vivo metabolic contexts.
GPX4 dependency was more pronounced in cancer cells adopting a therapy-resistant mesenchymal state than across a panel of non-transformed mesenchymal cell lines (Extended Data Fig. 9 ). We have discovered that this differential sensitivity can be further expanded by pre-treatment of cells with lipophilic antioxidants such as vitamin E (Extended Data Fig. 9 ; see also Fig. 4) , which indirectly complement the actions of GPX4 (ref. 8) . For example, the protective effects of vitamin E persisted longer in non-transformed mesenchymal cells compared to therapy-resistant cancer cells (Extended Data Fig. 9) , reminiscent of the differential effects of folinic acid between transformed and non-transformed cells in the context of methotrexatebased therapy 28 . We have defined, through perturbations and functional characterization, a pathway comprising thirteen distinct molecular nodes that underlies a broadly relevant mesenchymal therapy-resistant state and its dependency on a lipid-peroxidase pathway (Fig. 4) . This pathway centres on the synthesis, storage and use of long-chain polyunsaturated fatty acids (PUFAs) (for example, arachidonic acid), which are susceptible to becoming reactive lipid peroxides through the action of lipoxygenase enzymes 8 . GPX4 dissipates these reactive peroxides and thus protects against ferroptotic cell death 8 . Consistent with this model, we find that knockout of upstream regulators of PUFA metabolism (ACSL4, LPCAT3) 9 and inhibition of lipoxygenases prevent cell death due to inhibition of GPX4 (Extended Data Fig. 10) . A convergence on this theme is also consistent with the mesenchymal state-targeting compound ML239 (Fig. 1a) acting on fatty acid desaturase-2 (FADS2) to promote the generation of PUFAs that are substrates for lipid peroxidation 13 (Fig. 4) . By contrast, direct treatment of cells with a lipid peroxide does not show selectivity for cells in a mesenchymal state (Extended Data Fig. 10 ). This result supports that the GPX4-dependent feature of the therapy-resistant mesenchymal state we describe is not sensitivity to exogenous lipophilic peroxides themselves, but rather the propensity of specific cellular lipids to be substrates for lipid-oxidizing enzymes (Extended Data Fig. 10 ).
ZEB1, which we linked causally to GPX4 dependency (Fig. 3b) , provides a bridge between mesenchymal gene expression and lipidperoxide vulnerability 23 . ZEB1 has been shown to play an essential role in cellular lipid metabolism, in part through direct transcriptional regulation of PPARγ , a master regulator of lipid biology 22 . Growing evidence shows that ZEB1 regulates the uptake, accumulation and mobilization of lipids, and affects EMT-associated remodelling of the plasma membrane 29 , which is where lipoxygenase-mediated oxidation of PUFAs occurs. The resulting dependency of ZEB1-high cells on lipid-peroxidase activity is most effectively exploited by direct inhibition of GPX4, but can also be targeted through the suppression of GPX4 biosynthesis (statins) and distal perturbations of the metabolic pathways regulating the levels of the GPX4 cofactor glutathione (erastin, buthionine sulfoximine) 7, 8 (Extended Data Fig. 8 ). Dysregulation of the apoptotic cascade is characteristic of cancer cells in a therapy-resistance state and may explain their broad resistance to diverse therapeutic modalities 30 . Our results suggest that these same cells have an enhanced ability to undergo ferroptosis, a non-apoptotic form of cell death. More broadly, the results presented here illustrate an approach to understand and overcome cancer therapy resistance that transcends traditional approaches based on driver oncogenes and resistance mutations.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Figure 4 | Schematic of a pathway that characterizes a therapy-resistant mesenchymal cancer cell state and its dependency on lipid peroxide dissipation. This pathway centres on the ZEB1-dependent synthesis, storage and use of long-chain PUFAs, which are susceptible to becoming reactive lipid peroxides through the action of lipoxygenase enzymes. GPX4 dissipates these reactive peroxides and prevents their downstream iron-dependent reactions that ultimately result in ferroptotic cell death. Red text denotes chemical perturbations used to probe and uncover this circuitry; blue text denotes genetic perturbations that have been carried out. ACSL4, acyl-CoA synthetase long-chain family member 4; ALOX, arachidonate lipoxygenase; ALOXi, ALOX inhibitor; BSO, buthionine sulfoximine; GPX4, glutathione peroxidase 4; LPCAT3, lysophosphatidylcholine acyltransferase 3; sec-tRNA, selenocyteine tRNA; TGFβ , transforming growth factor-β ; ZEB1, zinc finger E-box binding homeobox 1.
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Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Omic datasets. Gene-expression data (RMA-processed, quantile normalized) were obtained from the CCLE portal (https://portals.broadinstitute.org/ccle/home). shRNA data and ATARiS gene solutions were obtained from the Project Achilles portal (http://portals.broadinstitute.org/achilles). Computation of mesenchymal score. Mesenchymal scores were computed by single-sample gene set enrichment analysis (ssGSEA) 12 , which estimates the degree of coordinate up-or downregulation of members of a given gene set within a transcriptionally profiled sample. Published EMT gene signatures 5, 6, 10 and Axl-positive melanoma gene signatures 2 were analysed using this method, yielding a single 'mesenchymal score' per signature for each cell line. Category-specific Δ-median AUC calculations (Fig. 1d) . For each class assignment (for example, bone lineage), a median AUC was computed for each compound across all cell lines belonging to the class. The median AUC for each compound across all cell lines not belonging to that class was then subtracted from the within-class median AUC, to yield a Δ -median AUC value. Non-adherent cell lines were excluded from this analysis. Significance testing was applied using a Student's t-test assuming unequal variance. Tests to evaluate AUC distributions for each compound within a given class assignment (for example, bone lineage) were regarded as a family of hypotheses for the purpose of multiple hypothesistest correction. Compounds within each class are plotted in rank order of their Δ -median AUC (smallest to largest). Compounds that meet a P value cut-off of 0.05 after correction for multiple hypothesis testing are plotted as larger dots than those compounds that do not meet the P value cut-off of 0.05. Correlation analyses. AUC values, as a metric of cell-line sensitivity to compound treatment 11 , were correlated with cellular features (gene-expression, geneknockdown sensitivity) 13 , ssGSEA-derived cell-line mesenchymal scores and with one another (across compounds). The number of cell lines used in individual correlation analyses, as well as specific cell-line exclusions (for example, exclusion of haematopoietic cell lines) are noted in the main text and figure legends. Correlation data are plotted as z scores computed analytically using Fisher's z transformation 31 to account for individual compounds having been exposed to different numbers of cell lines. Box-and-whisker plots and scatter plots were produced in GraphPad Prism. Clustering analysis. CTRP cluster (Fig. 2b) . Pairwise distances between compounds were computed using Pearson's correlation distances normalized by Fisher's z transformation to account for pairs of compounds exposed to different numbers of cell lines in common 31 . Normalized correlation z scores were further transformed using a monotonic double-sigmoid function to emphasize variation in the most relevant part of the resulting dendrograms 11, 31 . Non-adherent cell lines were excluded from the clustering application 11 . Cell lines. HT-1080 fibrosarcoma cells, LOXIMVI melanoma cells and WI38 lung fibroblasts were purchased from ATCC. RKN leiomyosarcoma were procured from HSRRB and KP4 pancreatic cancer cells from JCRB (Japan). Mesenchymal stem cells (MSCs), human umbilical vein endothelial cells (HUVECs) and haematopoietic progenitor (CD34 + ) cells were obtained from Lonza. BJeH foreskin fibroblasts were procured from the Weinberg laboratory (Whitehead Institute), MCF-7 ER-Snail1 cells 20 were obtained from the Haber laboratory (Massachusetts General Hospital), H358 ER-Twist1 cells 21 were obtained from the McCormick laboratory (UCSF) and gefitinib-sensitive and -resistant HCC4006 lung cancer cells 24 were obtained from the Engelman laboratory (Massachusetts General Hospital). M000921 and M980513 cells 27 were obtained from the Levesque laboratory (University of Zurich Hospital). AA01 and AA02 patient-derived cell lines were developed from ascites (AA01) or pleural fluid (AA02) of patients with metastatic pancreatic ductal adenocarcinoma using IRB-approved protocols at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital. Cells were cultured by the Cell Line Factory at the Broad Institute (https://portals. broadinstitute.org/cellfactory) using conditional reprogramming with a ROCK inhibitor and feeder cells as previously described 32 . In brief, each patient-derived sample was placed into culture on a layer of irradiated 3T3-J2 feeder cells in F-medium containing ROCK inhibitor. At passage number five, cell pellets were collected and KRAS mutation status was confirmed by targeted PCR-Sanger sequencing using isolated genomic DNA. Exome sequencing later confirmed the purity of the cell lines (99% tumour) and provided detailed mutational and copy-number characterization data. Cells were effectively grown in DMEM-based medium without ROCK inhibitor beyond passage number five.
HT-1080, WI38, MCF-7 ER-Snail1, AA01 and AA02 cells were maintained in DMEM, supplemented with 10% FBS and 1% penicillin-streptomycin (all medium components from Sigma-Aldrich). BJeH cells were maintained in 65% DMEM, 20% Medium 199 (Sigma-Aldrich) and 15% FBS supplemented with 1% penicillinstreptomycin. KP4 cells were cultured in a 1:1 ratio of DMEM:Ham's-F12 medium and RKN cells in Ham's-F12 medium, all supplemented with 10% FBS and 1% penicillin-streptomycin (Sigma-Aldrich). M000921 and M980513 cells 27 were maintained in RPMI supplemented with 5 mM glutamine, 1 mM sodium pyruvate and 10% heat-inactivated fetal calf serum (Invitrogen). HCC4006 gefitinibresistant cells were maintained in 10 μ M gefitinib (SelleckChem), which was replaced every three days. MSCs were grown in MSC growth medium (Lonza), HUVECs in EGM-2 medium (Lonza) and CD34 cells in serum-free HPGM medium (Lonza) supplemented with 25 ng ml −1 stem cell factor, 50 ng ml −1 thrombopoietin and 50 ng ml −1 FLT-3 ligand (all cytokines from Peprotech). Cell lines included in CTRP were recently validated with fingerprinting analysis. Selected cell lines were tested and confirmed as not having mycoplasma contamination using the commercially available MycoAlert kit. Compounds. 1S,3R-RSL3 was synthesized according to previously published protocols 8 . All other compounds were obtained from Broad Institute Compound Management Platform or purchased from SelleckChem or Sigma-Aldrich. Compound treatment. CTRP viability experiments 11, 13 were performed in 384-well format using opaque white plates (Corning). Twenty-four hours after seeding at optimized densities, cells were exposed to compounds at indicated concentrations for 72 h. Cellular ATP levels (as a surrogate for viability) were measured using CellTiter-Glo (Promega). For co-treatment experiments, spent medium was removed 24 h after cell seeding and replaced with medium containing a single concentration of the modulator of interest (for example, antioxidant). Compound treatment began one hour later. HCC4006 gefitinib-resistant cells 24 were exposed to compounds in the absence of gefitinib. For experiments characterizing GPX4 protein levels in fluvastatin-treated HT-1080 cells (Fig. 2c) , spent medium was removed every 48 h and replaced with fresh medium containing the indicated concentration of compound. Compound treatment of inducible mesenchymal state models. MCF-7 ERSnail1 cells 20 and H358 ER-Twist1 cells 21 were induced to undergo EMT with 1 μ M and 100 nM 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich), respectively, which was replaced every 72 h, for the number of indicated days. Induced cells were washed thoroughly to remove 4-OHT and were then exposed to compounds for 72 h (in the absence of 4-OHT). The upregulation of EMT-related genes in 4-OHTinduced cells under these conditions was confirmed using a Fluidigm Real-Time PCR system (Supplementary Table 3 ).
M000921 and M980513 melanoma cells 27 were treated with 5 ng ml −1 human recombinant TGFβ -1 (R&D Systems) for a minimum of 14 days, with TGFβ replaced every three days. Cells cultured in regular growth medium or supplemented with TGFβ were seeded in 96-well plates and treated with the indicated concentrations of PLX-4032 or RSL3 (Selleckchem). After 72 h, cell viability was measured by incubating cells for 2 h with a Resazurin solution (0.15 mg ml −1 in PBS) (Sigma-Aldrich) diluted 1:10 in regular growth medium. Fluorescence was read using a standard plate reader (Tecan) with excitation/emission of 535/595 nm. RSL3-fluvastatin synergy analysis (Fig. 2d) . HT-1080 cells were exposed to the indicated concentrations of fluvastatin for 48 h. At the end of this period, fluvastatin-containing medium was removed and replaced with medium containing the indicated concentrations of RSL3 and fluvastatin. Deviation from expected response was calculated assuming a Loewe additivity model for compound interactions 33 . Fig. 9 ). Cells that had been allowed to adhere overnight in 24-well dishes were exposed for 18 h to medium containing the indicated lipophilic antioxidant (2.5 μ M ferrostatin-1 (ref. 7) or 200 μ M α -tocopherol acetate). Following this exposure, cells were washed three times with 1 ml medium and three times with 1 ml PBS. Cells were then cultured continually in medium containing 0.5 μ M RSL3 for the duration of the experiment. Cells that became confluent during the course of the experiment were split directly into compound-containing medium. Cellular viability was assessed using CellTiter-Glo (Promega). Western blot. Cells were seeded in six-well dishes and cultured to 70% confluence. RIPA buffer (Thermo Scientific) supplemented with phosphatase inhibitor (Thermo Scientific) and protease inhibitor cocktails (Roche) was used to lyse cells. Lysate was centrifuged at 12,000 r.p.m. for 10 min at 4 °C and the protein concentration in the supernatant was quantified using a Bradford reagent (Bio-rad). Approximately 40 μ g of protein was mixed with sample buffer (Bio-rad) and boiled at 95 °C for 10 min, followed by incubation on ice for 5 min. Samples were separated by SDS-PAGE (Novex 4-12% Bis-Tris gel, Life Technologies) and transferred to a nitrocellulose membrane using an iBlot system (Life Technologies). Membranes were blocked with Odyssey Blocking Buffer (LI-COR) and incubated with primary antibodies overnight at 4 °C and LI-COR secondary antibodies for 1 h at room temperature. Membranes were imaged using the LI-COR Odyssey Imaging 
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